<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337934</url>
  </required_header>
  <id_info>
    <org_study_id>360/10</org_study_id>
    <nct_id>NCT01337934</nct_id>
  </id_info>
  <brief_title>Lactated Ringer Versus Albumin in Early Sepsis Therapy</brief_title>
  <acronym>RASP</acronym>
  <official_title>Ringer Versus Albumin In Septic Patients: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of albumin in critical ill patients is a matter of controversy. A large randomized
      controlled trial reported that albumin was as safe and effective as crystalloid solution for
      fluid replacement in intensive care unit, although the last one was less expensive. In
      Surviving Sepsis Campaign International Guidelines there are no preference for crystalloids
      over colloids. But recently, a retrospective analysis of patients with severe sepsis from
      SAFE study reported that the use of albumin in these patients would be superior, regarding
      reduction of mortality. The aim of this study is determine whether the use of albumin improve
      clinical outcomes in patients with severe sepsis or septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality in 7 days for any cause</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sequential organ failure assessment (SOFA) score</measure>
    <time_frame>from day 1 until day 7 of care in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator-free days</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Needing of renal replacement therapy</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days free of vasopressor</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in 28-days</measure>
    <time_frame>28 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Septic Shock</condition>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Lactated Ringer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactated Ringer</intervention_name>
    <description>Lactated Ringer</description>
    <arm_group_label>Lactated Ringer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Albumin 4%</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or higher than 18 years-old

          -  Severe sepsis or septic shock into 6 hours of evolution

          -  Written informed consent

        Exclusion Criteria:

          -  Shock from other causes

          -  Adverse reactions to human albumin

          -  Previous fluid resuscitation during current disease

          -  Previous use of albumin in the last 72 hours

          -  Religion objection

          -  Enrollment in another study

          -  Traumatic brain injury

          -  Hepatic cirrhosis

          -  End stage renal disease

          -  Plasmapheresis

          -  End of life patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliano A Almeida, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludhmila Hajjar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clarice H Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of Sao Paulo, School of Medicine, University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sao Paulo/SP</state>
        <zip>01246000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Fukushima J, Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Le√£o WC, Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO Jr. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010 Oct 13;304(14):1559-67. doi: 10.1001/jama.2010.1446.</citation>
    <PMID>20940381</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Juliano P Almeida, MD, PhD</investigator_full_name>
    <investigator_title>Instituto do Cancer do Estado de Sao Paulo</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Albumin</keyword>
  <keyword>Lactated Ringer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

